In a groundbreaking development, scientists have introduced a novel bacterial therapy for cancer that operates independently of the immune system, potentially transforming treatment for immunocompromised patients. This pioneering approach, developed by a research team led by Professor Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST), in collaboration with Daiichi Sankyo Co., Ltd. and the University of Tsukuba, involves a specially designed microbial consortium named AUN. Unlike traditional cancer immunotherapies that rely on immune cell activity, this innovative therapy leverages the synergistic effects of two bacterial strains.
The concept of bacterial cancer therapy has a long history, dating back to the late 19th century when early experiments demonstrated tumor regression upon intentional infection with bacteria. Over the years, this concept evolved into more advanced immunotherapies such as checkpoint inhibitors and CAR-T cells. While effective for some patients, these therapies are limited in their efficacy for individuals with compromised immune systems due to treatments like chemotherapy or radiotherapy. The new AUN therapy addresses this limitation by demonstrating potent antitumor effects independently of immune cell activity.
The AUN therapy combines two naturally occurring bacterial strains, A-gyo and UN-gyo, which work synergistically to achieve remarkable tumor clearance in both preclinical models and human studies, even under immunocompromised conditions. This unique approach not only showed strong biocompatibility and minimal side effects but also effectively prevented cytokine release syndrome (CRS), a common issue with some immunotherapies. The antitumor activity of AUN is driven by a coordinated interplay between the two bacterial species, highlighting the importance of their collaborative mechanisms in targeting cancer cells.
The regulatory partnership between A-gyo and UN-gyo plays a critical role in suppressing the pathogenicity of both strains while enhancing their tumor-specific cytotoxicity. This harmonious cooperation, reminiscent of the Japanese concept of “AUN” representing perfect harmony between opposites, underscores the efficacy of the therapy in achieving tumor clearance. With plans to launch a startup and initiate clinical trials within six years, Professor Eijiro Miyako envisions a new era in bacteria-based cancer therapy, offering a promising solution for patients who do not benefit from conventional immunotherapies.
This revolutionary approach represents a significant paradigm shift in cancer treatment, particularly for individuals with compromised immune systems. By introducing a therapy that operates independently of immune cells, the AUN therapy opens new possibilities for patients who have limited treatment options due to immunosuppression. With the potential to provide a more effective and tailored treatment approach, this innovative therapy holds promise for improving outcomes for cancer patients worldwide.
Takeaways:
– Bacteria-based cancer therapy presents a new frontier in cancer treatment by operating independently of the immune system.
– The AUN therapy combines two bacterial strains to achieve potent antitumor effects while avoiding reliance on immune cell activity.
– This innovative approach offers hope for immunocompromised cancer patients who may not benefit from traditional immunotherapies.
– The regulatory partnership between the bacterial strains A-gyo and UN-gyo demonstrates a unique mechanism of action in targeting cancer cells.
Tags: immunotherapy, biocompatibility, exosomes, clinical trials, regulatory
Read more on scitechdaily.com